Cargando…

IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease

BACKGROUND: Chronic mucocutaneous candidiasis (CMC) is defined by recurrent or persistent superficial infections involving nails, skin, and/or oral and genital mucosae. IL‐17 promotes the recruitment, chemotaxis, and expansion of neutrophils and acts directly on keratinocytes and epithelial cells, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chimenz, Roberto, Tropeano, Angelo, Chirico, Valeria, Ceravolo, Giorgia, Salpietro, Carmelo, Cuppari, Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306849/
https://www.ncbi.nlm.nih.gov/pubmed/35080300
http://dx.doi.org/10.1111/pai.13636
_version_ 1784752632920801280
author Chimenz, Roberto
Tropeano, Angelo
Chirico, Valeria
Ceravolo, Giorgia
Salpietro, Carmelo
Cuppari, Caterina
author_facet Chimenz, Roberto
Tropeano, Angelo
Chirico, Valeria
Ceravolo, Giorgia
Salpietro, Carmelo
Cuppari, Caterina
author_sort Chimenz, Roberto
collection PubMed
description BACKGROUND: Chronic mucocutaneous candidiasis (CMC) is defined by recurrent or persistent superficial infections involving nails, skin, and/or oral and genital mucosae. IL‐17 promotes the recruitment, chemotaxis, and expansion of neutrophils and acts directly on keratinocytes and epithelial cells, driving the production of antimicrobial peptides, essential for the immune response against Candida. AIM: To evaluate the serum level of IL‐17 in a family affected by CMC restricted to the nails of the hands and feet. METHODS: Serum IL‐17 was assayed on 16 patients (aged 21 ± 3.1 years) suffering from persistent onychomycosis caused by Candida and 18 healthy controls (aged 19 ± 2.7 years). Comparisons between groups were performed by Student's unpaired t‐test. The level of significance was set at 0.05. RESULTS: The mean serum IL‐17 level in patients was 74 ± 1.42 pg/ml, whereas the control group showed a significantly lower level of 25.6 ± 6.7 pg/ml (p < 0.05). CONCLUSIONS: We showed a potential defect in the IL‐17 signaling pathway in a family affected by CMC restricted to the nails of the hands and feet. Further research is needed to clarify the immunological mechanisms and the genetic etiology at the basis of the unusual clinical presentation in this family.
format Online
Article
Text
id pubmed-9306849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93068492022-07-28 IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease Chimenz, Roberto Tropeano, Angelo Chirico, Valeria Ceravolo, Giorgia Salpietro, Carmelo Cuppari, Caterina Pediatr Allergy Immunol Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology BACKGROUND: Chronic mucocutaneous candidiasis (CMC) is defined by recurrent or persistent superficial infections involving nails, skin, and/or oral and genital mucosae. IL‐17 promotes the recruitment, chemotaxis, and expansion of neutrophils and acts directly on keratinocytes and epithelial cells, driving the production of antimicrobial peptides, essential for the immune response against Candida. AIM: To evaluate the serum level of IL‐17 in a family affected by CMC restricted to the nails of the hands and feet. METHODS: Serum IL‐17 was assayed on 16 patients (aged 21 ± 3.1 years) suffering from persistent onychomycosis caused by Candida and 18 healthy controls (aged 19 ± 2.7 years). Comparisons between groups were performed by Student's unpaired t‐test. The level of significance was set at 0.05. RESULTS: The mean serum IL‐17 level in patients was 74 ± 1.42 pg/ml, whereas the control group showed a significantly lower level of 25.6 ± 6.7 pg/ml (p < 0.05). CONCLUSIONS: We showed a potential defect in the IL‐17 signaling pathway in a family affected by CMC restricted to the nails of the hands and feet. Further research is needed to clarify the immunological mechanisms and the genetic etiology at the basis of the unusual clinical presentation in this family. John Wiley and Sons Inc. 2022-01-25 2022-01 /pmc/articles/PMC9306849/ /pubmed/35080300 http://dx.doi.org/10.1111/pai.13636 Text en © 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
Chimenz, Roberto
Tropeano, Angelo
Chirico, Valeria
Ceravolo, Giorgia
Salpietro, Carmelo
Cuppari, Caterina
IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
title IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
title_full IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
title_fullStr IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
title_full_unstemmed IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
title_short IL‐17 serum level in patients with chronic mucocutaneous candidiasis disease
title_sort il‐17 serum level in patients with chronic mucocutaneous candidiasis disease
topic Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306849/
https://www.ncbi.nlm.nih.gov/pubmed/35080300
http://dx.doi.org/10.1111/pai.13636
work_keys_str_mv AT chimenzroberto il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease
AT tropeanoangelo il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease
AT chiricovaleria il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease
AT ceravologiorgia il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease
AT salpietrocarmelo il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease
AT cupparicaterina il17serumlevelinpatientswithchronicmucocutaneouscandidiasisdisease